Clinical trials: Myeloid Tumor
Acute Myeloid Leukemia
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
The purpose of this observational study is to assess the real-world safety of maintenance therapy with oral azacitidine in Korean participants with acute myeloid leukemia (AML) who achieved first complete remission (CR) or…
- Trial name
- NCT06073769
- Testing
- Oral azacitidine
- Where
- 2 sites in South Korea
- Volunteers
- 154 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens
- Conditions
- Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL), Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
- Trial name
- NCT01066468
- Testing
- Gleevec/Glivec
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukaemia
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
The treatment of CML and the expected survival has been revolutionised since the introduction of tyrosine kinase inhibitors (TKIs) such as nilotinib.
- Trial name
- PInNACLe (NCT02001818)
- Testing
- Nilotinib, Pegylated interferon alpha-2b, Imatinib
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00008190
- Testing
- aldesleukin, filgrastim, busulfan
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Leukemia, Myeloid
ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML
"In daily clinical practice, 2022 ELN guidelines were used to predict response to conventional treatment and to guide the need for allogenic stem cell transplantation.
- Trial name
- NCT06512610
- Testing
- Middle Eastern or North Coast of Africa patients with newly AML
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Leukemia, Myelodysplastic Syndromes
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Phase I trial to study the effectiveness of 6-hydroxymethylacylfulvene in treating patients who have refractory myelodysplastic syndrome, acute myeloid leukemia, acute lymphocytic leukemia, or blastic phase chronic myelogenous…
- Trial name
- NCT00003997
- Testing
- irofulven
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Minimal Residual Disease
Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
Study purpose is to assess the prognostic role of Minimal Residual Disease (defined as medullary expression of WT1 gene), performed at Baseline and during treatment according to clinical practice.
- Conditions
- Acute Myeloid Leukemia, Minimal Residual Disease, Wilms Tumor
- Trial name
- LAM-MMR (NCT02714790)
- Volunteers
- 281 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Acute Myeloid Leukemia (AML)
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
This was a non-interventional, retrospective registry study, utilizing electronic health record (EHR) data collected in the hospital district of Helsinki and Uusimaa (HUS).
- Trial name
- NCT05488613
- Testing
- Midostaurin
- Where
- Finland
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of…
- Trial name
- ADVANCE (NCT02643420)
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 406 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of patients with relapsed and/or refractory Acute Myeloid…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00569010
- Testing
- Azacitidine, Ara-C
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
The goal of this clinical research study is to study how effective treatments with clofarabine alone and clofarabine given in combination with ara-C are in the treatment of leukemia and high-risk myelodysplastic syndrome (MDS) in…
- Trial name
- NCT00088218
- Testing
- Clofarabine, Ara-C
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer, Solid Tumor, Adult
Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients
The goal of this observational study is to measure and try to reduce leakage in precision medicine care in the community cancer clinic.
- Conditions
- Advanced Cancer, Solid Tumor, Adult, Myeloid Malignancy
- Trial name
- NCT06090513
- Testing
- Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation, limited genetic testing or no testing
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Bien-Willner Physicians Group PA
Acute Myeloid Leukemia
Transfusion in Adult Acute Myeloid Leukemia
Acute myeloid leukaemia (AML) is a haematological malignant disease characterized by an uncontrolled proliferation of immature hematopoietic cells.
- Trial name
- NCT02899767
- Volunteers
- 1,067 people
- Sponsor
- Hospices Civils de Lyon
Hematologic Malignancy
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB)…
- Trial name
- HTLP-ONCO (NCT04707300)
- Testing
- Human T Lymphoid Progenitor (HTLP) injection
- Where
- 5 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia
Natural Killer Index From Hematopoietic Stem Cell Graft
Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between KIR and HLA for couple…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT00435864
- Testing
- Blood test
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Leukemia, Myelodysplastic Syndromes
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
RATIONALE: Giving chemotherapy, such as busulfan, fludarabine, and melphalan, before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal or cancer cells and prepares the patient's bone marrow for…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT00357565
- Testing
- filgrastim, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia
Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia
This is a pilot study comparing 3 arms (standard care with hypnosis / standard care with virtual reality / standard care alone), aimed at measuring the effect on anxiety during the induction treatment.
- Trial name
- HYPNO-RV LAM (NCT07386392)
- Testing
- Hypnosis, Virtual Reality
- Where
- France
- Volunteers
- 99 people
- Sponsor
- University Hospital, Toulouse
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1
Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation
This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes
- Trial name
- VICTORY (NCT05005299)
- Testing
- Venetoclax, Fludarabine, Cyclophosphamide
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Melbourne Health
Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria
Unrelated Donor Stem Cell Transplantation
The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells…
- Conditions
- Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT01364363
- Testing
- Allogeneic transplantation
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Scripps Health
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis
The purpose of this study is to determine whether cyclophosphamide post bone marrow transplant increases the rate of patients alive, in remission and without immunosuppression, one year after transplant, when compared with the…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Myeloproliferative Disease, Myelodysplastic Syndrome
- Trial name
- CICLODECH (NCT01749111)
- Testing
- ARM A Cyclophosphamide, ARM B Calcineurin inhibitor and methotrexate
- Where
- Brazil
- Volunteers
- 3 people
- Sponsor
- Hospital Israelita Albert Einstein
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.